Dublin, Sept. 22, 2023 (GLOBE NEWSWIRE) -- The "Global Bronchial Spasms Treatment Market Report and Forecast 2023-2031" report has been added to ResearchAndMarkets.com's offering.
The global bronchial spasms treatment market, valued at USD 351.8 million in 2022, is expected to grow at a CAGR of 4.1% during the forecast period of 2023-2031, reaching a market value of USD 505.07 million by 2031. This growth can be attributed to the increasing prevalence of respiratory diseases and the rising awareness surrounding bronchial spasms treatment.
Bronchial spasms treatment involves medical care for individuals experiencing bronchial spasms, a condition characterized by sudden muscle tightening around the airways, leading to breathing difficulties. Treatment options include medication, inhalers, and supportive services such as pulmonary rehabilitation and breathing exercises. The market's growth is driven by factors like the rising prevalence of respiratory diseases (e.g., asthma and COPD), increasing awareness about bronchial spasms, government initiatives, and a growing demand for innovative treatments.
Technological advancements, particularly in digital health tools like telemedicine and online therapy platforms, have made bronchial spasms treatment more accessible, further expanding its reach and meeting the rising demand for services.
Bronchial Spasms Epidemiology
Globally, approximately 339 million people suffer from asthma, and more than 251 million individuals are affected by COPD. Both conditions can lead to bronchial spasms, increasing the demand for bronchial spasms treatment. It's crucial to recognize that bronchial spasms can vary among individuals, necessitating personalized treatment.
Efforts to improve access to bronchial spasms treatment should consider the unique needs of different age and gender groups, as well as factors like genetics, environment, and lifestyle. Addressing these factors can reduce the burden of respiratory diseases and enhance access to effective treatment for everyone.
The bronchial spasms treatment market can be segmented as follows:
- Imaging Test
- Spirometry Test
- Short-acting Bronchodilators
- Long-acting Bronchodilators
- Inhaled Steroids
- Oral or Intravenous Steroids
- Homecare Settings
- North America
- Asia Pacific
- Latin America
- Middle East and Africa
Bronchial Spasms Treatment Market Analysis
The global bronchial spasms treatment market has experienced significant growth, driven by factors like increasing respiratory disease prevalence, awareness about bronchial spasms, and demand for innovative treatments. North America leads the market due to high respiratory disease prevalence, a well-established healthcare system, and substantial investment in respiratory health R&D.
Europe is another significant market with countries like the United Kingdom, Germany, and France at the forefront. The region benefits from a large population, growing respiratory health awareness, and government initiatives. Asia Pacific is witnessing substantial market growth driven by its large population, increasing awareness of respiratory health, and adoption of digital respiratory health technologies.
Key Market Players
Key players in the bronchial spasms treatment market include:
- Novartis International AG
- GSK plc
- Merck & Co., Inc
- AstraZeneca plc
- C. H. Boehringer Sohn Co. KG
- Teva Pharmaceutical Industries Ltd
- Viatris Inc
- Sunovion Pharmaceuticals Inc
- Amphstar Pharmaceuticals, Inc
- Pfizer, Inc.
|No. of Pages
|2023 - 2031
|Estimated Market Value (USD) in 2023
|Forecasted Market Value (USD) by 2031
|Compound Annual Growth Rate
For more information about this report visit www.researchandmarkets.com/r/5332vq
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.